Earnings summaries and quarterly performance for NAOV.
Executive leadership at NAOV.
Board of directors at NAOV.
Research analysts covering NAOV.
Recent press releases and 8-K filings for NAOV.
ENvue Medical's UroShield® Kit Secures UK Reimbursement
NAOV
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- ENvue Medical, Inc. announced that its UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK.
- This reimbursement milestone is coupled with an initial purchase order from Peak Medical, a UK distributor, providing early revenue visibility for 2026.
- The UroShield® Kit is a non-invasive device designed to reduce catheter-associated urinary tract infections (CAUTIs) and catheter blockages.
Dec 18, 2025, 5:30 PM
NanoVibronix Announces Strategic Shift to ENvue Platform and Planned Rebranding
NAOV
New Projects/Investments
Revenue Acceleration/Inflection
M&A
- NanoVibronix, Inc. is shifting its strategic focus to the ENvue® Feeding Tube Placement System as its core growth platform, which is 510(k) FDA-cleared and commercially available.
- The company plans to rebrand from NanoVibronix to ENvue Medical and will introduce a new NASDAQ ticker symbol to reflect this new strategic direction.
- The ENvue system operates in the U.S. enteral feeding devices market, which is projected to reach approximately $1.8 billion by 2030, and currently has an established customer base of 38 hospitals.
- NanoVibronix is actively exploring strategic alternatives for its legacy technologies, such as partnerships or divestitures, to maximize value and focus on enteral navigation.
Nov 19, 2025, 1:00 PM
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering
NAOV
- NanoVibronix, Inc. announced a registered direct offering of 291,204 shares of its common stock (or common stock equivalents) at an offering price of $7.01 per share.
- The offering is expected to generate approximately $2.0 million in gross proceeds and $1.8 million in net proceeds.
- The company intends to use the net proceeds for general working capital purposes, including repayment of certain outstanding indebtedness and/or redemption of certain outstanding preferred stock.
- The closing of the offering is expected to occur on or about September 17, 2025.
Sep 17, 2025, 8:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more